TABLE 4.

Progression-free and overall survival rates for recurrent medulloblastoma in large series

Author	Number of patients with standard chemo, or RT, or both upfront	Intervention	Survival
Koschmann et al.24	14	Chemo (temozolomide, irinotecan, CCNU, topotecan, vorinostat, isotretinoin, HD chemo/stem cells (N = 10), re-RT (N = 6), gamma knife (N = 5), re-CSI (N = 2), surgery (N = 3), phase I trials (N = 4)	Median survival 10.3 months (1.3–80.5)
Gururangan et al.3	30	HD chemo/stem cells (N = 19), or standard salvage chemo (cyclophosphamide, etoposide, platinum compounds, methotrexate, irinotecan temozolomide, intrathecal busulfan, or VNP40101M +/− RT (N = 11); with or without re-RT	3-year overall survival for previously nonirradiated patients 14%; previously irradiated patients median follow-up of 35 months (range, 7–49 months), all died of progressive disease; standard salvage patients all died median 26 months (range, 3–112 months)
Shih et al.25	13	HD chemo/stem cells
Dunkel et al.2	25	HD chemo/stem cells +/− focal RT or CSI	6/25 progression-free survivors; progressive disease median 8.5 months (N = 16) ; 3 died of toxicity
Bakst et al.26	11	Re-RT +/− surgery	Median F/U 30 months; PFS 48% at 5 years
Robison et al.27	8	5 drug oral regimen (continuous oral celecoxib, thalidomide, fenofibrate, alternating 21-day cycles cyclophosphamide, etoposide)	1CR, 1 PR, 1SD, 5 PD

HD, high dose; chemo, chemotherapy; RT, radiation therapy; CSI, craniospinal radiation therapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.